Corporate governance issues are of critical importance to large investors evaluating investment opportunities. Mega-cap companies in the biopharmaceutical space (>$75B market cap) have aligned their governance structures to best practices across the S&P 500. Although not far behind mega-cap peers in many respects, large-cap biopharmaceutical companies ($10B to $45B market cap) have occasionally lagged in adopting those trends.